2023 Annual Meeting | H337 - Lecanemab: A Practical Perspective (Practice and Policy Hub)

Date Thursday 04/27/23

Time 01:30 PM - 02:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Hubs (Practice and Policy)

Director(s) Katherine Coerver, MD, PhD, FAAN

Topic(s) Practice, Policy, and Ethics

Learning Objectives Participants should be able to understand and identify which patient population may benefit from the use of anti-amyloid therapy, describe the resources necessary to screen and monitor patients who may be receving anti-amyloid therapy, detail a potential work flow to help offices access patients while receiving therapy, and recognize the potential issues which may occur with use of these medications.

CME Available 0.50 CME credit

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism

Program Level Introductory

Program Tracks Business of Neurology

Recommended Audience General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Didactic

Event Timeline
01:30 PM - 02:00 PM EST	Speaker	Lecanemab: A Practical Perspective Katherine Coerver, MD, PhD, FAAN

Faculty Disclosures
Katherine Coerver, MD, PhD, FAAN	Dr. Coerver has received personal compensation for serving as an employee of CenExel. Dr. Coerver has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai . Dr. Coerver has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai . Dr. Coerver has received research support from Lilly. Dr. Coerver has received research support from Annovis. Dr. Coerver has received research support from Biogen.